INM Research and Charts

INM - InMed Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-01-03)

Last 4.96	Change ⇑ +0.16 (+3.33%)	Volume 15,523
	Open 4.77	High 4.99	Low 4.76

8EMA (Daily) 4.75	40EMA (Daily) 3.92	50EMA (Daily) 3.58	STO (Daily) 52.245	MACD Hist (Daily) -0.169
8EMA (Weekly) 4.189	40EMA (Weekly) 1.84	50EMA (Weekly) 1.77	STO (Weekly) 76.490	MACD Hist (Weekly) 0.693


Company Profile
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; NM-088 for the treatment of glaucoma; and IntegraSyn.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.